Thomas Sannié
Research Subjects
Thomas Sannié has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Roseline D Oiron
Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Rares, Hôpital Bicêtre APHP, and HITh, UMR_S1176, INSERM Université Paris‐Saclay, Le Kremlin‐Bicêtre Paris France
5 shared publications - Mark W. Skinner
Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada
4 shared publications - Annie Harroche
Service d'Hématologie Clinique Centre de Traitement de l'Hémophilie Hôpital Necker Enfants Malades, AP‐HP Paris France
3 shared publications Any Beltran Anzola
CEReSS / UR 3279, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University, Marseille, France
3 shared publicationsHervé Chambost
Haemophilia Treatment Centre, Children Hospital La Timone, University Hospital of Marseille (AP-HM), Marseille, France
3 shared publications- Ngoc Anh Thu Nguyen
CEReSS / UR 3279, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University, Marseille, France
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 149, 109645
Exploring patients' and caregivers' experience of therapeutic patient education in rare diseases: A qualitative study
- 17 April 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 149, 109645
Open AccessExploring patients' and caregivers' experience of therapeutic patient education in rare diseases: A qualitative study
- 28 February 2026
- Published by Wiley in Haemophilia
- Vol. 32 (3) , 680-690
Implementing Shared Decision‐Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi‐Stakeholder Delphi Process
Introduction: Shared decision‐making (SDM) is a collaborative process in which people with haemophilia (PWH) and healthcare professionals (HCPs) make treatment decisions informed by the best available evidence and aligned with patient values, preferences and goals. The expanding treatment landscape, including standard, extended and ultra‐half‐life factors, rebalancing agents, bispecific antibodies and gene therapy, has made SDM an essential element of quality haemophilia care. Despite recognition of its importance in international health policy frameworks and haemophilia‐specific guidelines, implementation in clinical practice remains inconsistent, with limited guidance on best practices. Aim: To address this gap, the World Federation of Hemophilia (WFH), in partnership with the European Association for Haemophilia and Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC), took a multi‐stakeholder consensus initiative to develop best practice statements for SDM in haemophilia. Methods: A structured, modified Delphi process was used during a March 2025 workshop in Lisbon, Portugal, with 27 participants (13 HCPs and 14 PWH) from 15 Western European countries. Participants identified key challenges, drafted candidate statements and engaged in two rounds of anonymous voting with predefined consensus thresholds. Following literature review and facilitated small‐ and large‐group discussions, 20 candidates’ best practice (BP) statements were drafted and voted on in 2 Delphi rounds. Consensus was defined as ≥70% of participants rating a statement 7–9 (critical to include) and ≤15% rating 1–3 (not important). Results: Iterative refinement yielded 15 BP statements achieving consensus. These were organized into three domains: (1) knowledge and tools, (2) patient characteristics and support and (3) HCP—PWH relationship and system infrastructure. Recommendations emphasized embedding SDM into routine care, ensuring adequate time and resources as well as early patient preparation, accessible information in local languages, multidisciplinary involvement and reflection opportunities post consultation. Conclusion: To the best of the authors’ knowledge, this work represents the first consensus‐based framework for implementing SDM in haemophilia, offering practical, stakeholder‐driven guidance to support its integration into clinical practice and improve patient‐centred outcomes.
- 28 February 2026
- Published by Wiley in Haemophilia
- Vol. 32 (3) , 680-690
Implementing Shared Decision‐Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi‐Stakeholder Delphi Process
Introduction: Shared decision‐making (SDM) is a collaborative process in which people with haemophilia (PWH) and healthcare professionals (HCPs) make treatment decisions informed by the best available evidence and aligned with patient values, preferences and goals. The expanding treatment landscape, including standard, extended and ultra‐half‐life factors, rebalancing agents, bispecific antibodies and gene therapy, has made SDM an essential element of quality haemophilia care. Despite recognition of its importance in international health policy frameworks and haemophilia‐specific guidelines, implementation in clinical practice remains inconsistent, with limited guidance on best practices. Aim: To address this gap, the World Federation of Hemophilia (WFH), in partnership with the European Association for Haemophilia and Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC), took a multi‐stakeholder consensus initiative to develop best practice statements for SDM in haemophilia. Methods: A structured, modified Delphi process was used during a March 2025 workshop in Lisbon, Portugal, with 27 participants (13 HCPs and 14 PWH) from 15 Western European countries. Participants identified key challenges, drafted candidate statements and engaged in two rounds of anonymous voting with predefined consensus thresholds. Following literature review and facilitated small‐ and large‐group discussions, 20 candidates’ best practice (BP) statements were drafted and voted on in 2 Delphi rounds. Consensus was defined as ≥70% of participants rating a statement 7–9 (critical to include) and ≤15% rating 1–3 (not important). Results: Iterative refinement yielded 15 BP statements achieving consensus. These were organized into three domains: (1) knowledge and tools, (2) patient characteristics and support and (3) HCP—PWH relationship and system infrastructure. Recommendations emphasized embedding SDM into routine care, ensuring adequate time and resources as well as early patient preparation, accessible information in local languages, multidisciplinary involvement and reflection opportunities post consultation. Conclusion: To the best of the authors’ knowledge, this work represents the first consensus‐based framework for implementing SDM in haemophilia, offering practical, stakeholder‐driven guidance to support its integration into clinical practice and improve patient‐centred outcomes.
- Open Access
- 11 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1197-1208
Navigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project
Introduction: Haemophilia causes spontaneous or prolonged bleeding due to a deficiency in clotting factor VIII (haemophilia A) or IX (haemophilia B). Although substitutive therapies and regular follow‐up can prevent severe haemorrhagic events, adherence to treatment remains a challenge. Transitioning from adolescence to adulthood and from paediatric to adult care is particularly complex for young people with severe haemophilia (PwSH), as it involves gaining autonomy in health management. Objectives: This study aimed to explore factors influencing the success of the transition process in young PwSH, with a focus on adherence to healthcare. Methods: This qualitative study was part of the mixed‐methods TRANSHEMO project. Participants were selected from the quantitative phase of the TRANSHEMO project based on two criteria: adolescents/young adults and adherent/nonadherent to healthcare. Interviews were conducted via video conferencing, transcribed, and thematically analysed to identify key themes affecting the transition process. Results: Twenty‐two interviews were conducted. Four major themes emerged as critical to transition success: (1) Care factors [continuity of care, treatment rituals, and evolving therapies]; (2) Family and social factors [support from family, friends, peers, and overprotection]; (3) Personal factors [understanding haemophilia, risk management, optimism, and coping strategies]; and (4) Autonomy [secondary benefits, independence, proactivity in disease management, and accompaniment by caregivers]. Conclusion: Based on the enlightened determinants, supportive strategies and patient education programs should focus on the development of autonomy, personal factors such as acquisition and application of health literacy in haemophilia care, and family factors such as support from family.
- 11 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1197-1208
Open AccessNavigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project
Introduction: Haemophilia causes spontaneous or prolonged bleeding due to a deficiency in clotting factor VIII (haemophilia A) or IX (haemophilia B). Although substitutive therapies and regular follow‐up can prevent severe haemorrhagic events, adherence to treatment remains a challenge. Transitioning from adolescence to adulthood and from paediatric to adult care is particularly complex for young people with severe haemophilia (PwSH), as it involves gaining autonomy in health management. Objectives: This study aimed to explore factors influencing the success of the transition process in young PwSH, with a focus on adherence to healthcare. Methods: This qualitative study was part of the mixed‐methods TRANSHEMO project. Participants were selected from the quantitative phase of the TRANSHEMO project based on two criteria: adolescents/young adults and adherent/nonadherent to healthcare. Interviews were conducted via video conferencing, transcribed, and thematically analysed to identify key themes affecting the transition process. Results: Twenty‐two interviews were conducted. Four major themes emerged as critical to transition success: (1) Care factors [continuity of care, treatment rituals, and evolving therapies]; (2) Family and social factors [support from family, friends, peers, and overprotection]; (3) Personal factors [understanding haemophilia, risk management, optimism, and coping strategies]; and (4) Autonomy [secondary benefits, independence, proactivity in disease management, and accompaniment by caregivers]. Conclusion: Based on the enlightened determinants, supportive strategies and patient education programs should focus on the development of autonomy, personal factors such as acquisition and application of health literacy in haemophilia care, and family factors such as support from family.
- 5 October 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1298-1308
Development of the World Federation of Hemophilia Shared Decision‐Making Tool
Introduction: The use of shared decision‐making (SDM) in clinical settings is becoming more prevalent. The evolving and increasingly complex treatment landscape of haemophilia management has augmented the need and desire for SDM between patients and their healthcare team. SDM tools have been used in other chronic conditions and can be an effective form of education for patients and clinicians.Aim: The World Federation of Hemophilia (WFH) partnered with people with haemophilia (PWH), patient advocacy groups, and healthcare practitioners to form an expert working group to develop an educational tool for PWH and their caregivers. The primary objectives included educating PWH on the available prophylactic treatments and facilitating discussion between PWH and their healthcare team.Methods: The tool was proposed and developed by the expert working group, workshopped at conference round tables, and evaluated in two focus groups.Results: The interactive WFH SDM Tool guides users through the SDM treatment journey and provides an opportunity for reflection on current disease impact and treatment preferences, educational fact sheets and videos, and a comparison between treatment classes. Two forms of the SDM Tool are available: an online platform with a summary page that may be printed and shared and a printable workbook. All evidence in the tool is based on the prescribing information or phase III clinical trial publications. The Tool will be updated twice each year.Conclusion: The WFH SDM Tool is the first available resource that translates published guidance on SDM in haemophilia into a practical, user‐friendly tool aimed at facilitating patient‐centred treatment decisions.
- 5 October 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1298-1308
Development of the World Federation of Hemophilia Shared Decision‐Making Tool
Introduction: The use of shared decision‐making (SDM) in clinical settings is becoming more prevalent. The evolving and increasingly complex treatment landscape of haemophilia management has augmented the need and desire for SDM between patients and their healthcare team. SDM tools have been used in other chronic conditions and can be an effective form of education for patients and clinicians.Aim: The World Federation of Hemophilia (WFH) partnered with people with haemophilia (PWH), patient advocacy groups, and healthcare practitioners to form an expert working group to develop an educational tool for PWH and their caregivers. The primary objectives included educating PWH on the available prophylactic treatments and facilitating discussion between PWH and their healthcare team.Methods: The tool was proposed and developed by the expert working group, workshopped at conference round tables, and evaluated in two focus groups.Results: The interactive WFH SDM Tool guides users through the SDM treatment journey and provides an opportunity for reflection on current disease impact and treatment preferences, educational fact sheets and videos, and a comparison between treatment classes. Two forms of the SDM Tool are available: an online platform with a summary page that may be printed and shared and a printable workbook. All evidence in the tool is based on the prescribing information or phase III clinical trial publications. The Tool will be updated twice each year.Conclusion: The WFH SDM Tool is the first available resource that translates published guidance on SDM in haemophilia into a practical, user‐friendly tool aimed at facilitating patient‐centred treatment decisions.
- 29 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 1071-1076
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project
- 29 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 1071-1076
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project
- 17 September 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1456-1466
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders
Introduction: Inherited bleeding disorders (IBD) are genetic conditions that affect blood clotting, leading to complications such as prolonged or spontaneous bleeding into muscles or joints. Early identification and treatment are crucial to prevent complications and improve outcomes. However, effective patient outreach and identification programs for IBD face significant challenges globally.Aim: This study aimed to identify successful patient outreach initiatives for IBD, barriers encountered during implementation, and approaches used to overcome them.Methods: The World Federation of Haemophilia (WFH) conducted a survey of its national member organizations and other patient associations, totalling 153 organizations, to identify common strategies, barriers to their implementation, and solutions for outreach and the identification of people with IBD. The survey consisted of both closed‐ended and open‐ended questions, and the data were analysed using descriptive statistics and thematic analysis.Results: Common challenges included resource and sustainability‐related aspects such as financial constraints, limited lab equipment for diagnosis, and inadequate government commitment. Significant barriers also encompassed physical/geographical challenges like difficulty accessing remote areas, and inadequate logistical support and transportation. Seven themes emerged to enhance patient outreach: resource mobilization; awareness‐raising and advocacy; knowledge and capacity building; collaboration and partnership; decentralization of services; improved logistical support and infrastructure; utilization of technology and innovation; and financial aid and incentives.Conclusion: Multistakeholder collaboration, coupled with secured government commitment, is crucial for improving global outreach, diagnosis rates, and access to care for individuals with IBD. Customized outreach programs should consider regional contexts, financial constraints, and prioritize innovation.
- 17 September 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1456-1466
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders
Introduction: Inherited bleeding disorders (IBD) are genetic conditions that affect blood clotting, leading to complications such as prolonged or spontaneous bleeding into muscles or joints. Early identification and treatment are crucial to prevent complications and improve outcomes. However, effective patient outreach and identification programs for IBD face significant challenges globally.Aim: This study aimed to identify successful patient outreach initiatives for IBD, barriers encountered during implementation, and approaches used to overcome them.Methods: The World Federation of Haemophilia (WFH) conducted a survey of its national member organizations and other patient associations, totalling 153 organizations, to identify common strategies, barriers to their implementation, and solutions for outreach and the identification of people with IBD. The survey consisted of both closed‐ended and open‐ended questions, and the data were analysed using descriptive statistics and thematic analysis.Results: Common challenges included resource and sustainability‐related aspects such as financial constraints, limited lab equipment for diagnosis, and inadequate government commitment. Significant barriers also encompassed physical/geographical challenges like difficulty accessing remote areas, and inadequate logistical support and transportation. Seven themes emerged to enhance patient outreach: resource mobilization; awareness‐raising and advocacy; knowledge and capacity building; collaboration and partnership; decentralization of services; improved logistical support and infrastructure; utilization of technology and innovation; and financial aid and incentives.Conclusion: Multistakeholder collaboration, coupled with secured government commitment, is crucial for improving global outreach, diagnosis rates, and access to care for individuals with IBD. Customized outreach programs should consider regional contexts, financial constraints, and prioritize innovation.
- 12 August 2023
- Published by Wiley in Haemophilia
- Vol. 29 (5) , 1202-1218
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐sectional study based on the FranceCoag registry
Introduction: It is necessary to gain insights into adherence to healthcare in people with severe haemophilia (PwSH), especially during the transition from paediatric to adult care, which is an important phase in lives of young people with childhood chronic disease. This adherence can be considered as a marker of successful transition.Objectives: The main objective of the quantitative phase of the TRANSHEMO project was to compare the adherence to healthcare between adolescents and young adults (YAs) with severe haemophilia. The secondary objective was to identify the determinants (facilitators and barriers) of this adherence and associations between these determinants.Methods: A multicentre, observational, cross‐sectional study was conducted in 2017–2019 on PwSH aged between 14 and 17 years (adolescents) or between 20 and 29 years (YAs), included in the FranceCoag registry and having completed the questionnaires. The adherence to healthcare (treatment regimens and clinical follow‐up) was compared between adolescents and YAs using the chi‐squared test. The determinants of this adherence were analysed by structural equation modelling.Results: There were 277 participants, 107 adolescents, and 170 YAs. The rate of adolescents adhering to healthcare was 82.2%, while the rate of YAs was 61.2% (p < .001). The barriers to the adherence to healthcare were being YA, having repeated at least one school grade and presenting mental health concerns.Conclusion: Adolescents had better adherence to healthcare than YAs. According to the determinants enlightened in this project, targeted supportive strategies and adapted therapeutic education programs can be developed for young PwSH to facilitate their adherence to healthcare.
- 12 August 2023
- Published by Wiley in Haemophilia
- Vol. 29 (5) , 1202-1218
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐sectional study based on the FranceCoag registry
Introduction: It is necessary to gain insights into adherence to healthcare in people with severe haemophilia (PwSH), especially during the transition from paediatric to adult care, which is an important phase in lives of young people with childhood chronic disease. This adherence can be considered as a marker of successful transition.Objectives: The main objective of the quantitative phase of the TRANSHEMO project was to compare the adherence to healthcare between adolescents and young adults (YAs) with severe haemophilia. The secondary objective was to identify the determinants (facilitators and barriers) of this adherence and associations between these determinants.Methods: A multicentre, observational, cross‐sectional study was conducted in 2017–2019 on PwSH aged between 14 and 17 years (adolescents) or between 20 and 29 years (YAs), included in the FranceCoag registry and having completed the questionnaires. The adherence to healthcare (treatment regimens and clinical follow‐up) was compared between adolescents and YAs using the chi‐squared test. The determinants of this adherence were analysed by structural equation modelling.Results: There were 277 participants, 107 adolescents, and 170 YAs. The rate of adolescents adhering to healthcare was 82.2%, while the rate of YAs was 61.2% (p < .001). The barriers to the adherence to healthcare were being YA, having repeated at least one school grade and presenting mental health concerns.Conclusion: Adolescents had better adherence to healthcare than YAs. According to the determinants enlightened in this project, targeted supportive strategies and adapted therapeutic education programs can be developed for young PwSH to facilitate their adherence to healthcare.
- Open Access
- 20 July 2022
- Published by Wiley in Haemophilia
- Vol. 28 (6) , 962-976
Occupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry
Introduction: Health of people with severe haemophilia (PwSH) improves thanks to the advancements in haemophilia care, giving them more opportunities in occupational integration. However, there is little literature on the occupational integration of PwSH.Objectives: The main objective of our study was to assess the occupational integration of PwSH and to compare it with that of the general population. The secondary objective was to study the association between individual characteristics (sociodemographic, clinical and psycho‐behavioural) and occupational integration of PwSH.Methods: A multicentre, non‐interventional, cross‐sectional study was conducted in 2018–2020 on PwSH, aged over 18 and under 65 years and included in the FranceCoag registry. Measurements included indicators of occupational integration, sociodemographic, clinical and psycho‐behavioural characteristics. The indicators of occupational integration were compared with those of the general population, using indirect standardization. The data of the general population were available from the National Institute of Statistics and Economic Studies (INSEE). Determinants of occupational integration were explored using structural equation modelling.Results: Of 1262 eligible people, 588 were included. PwSH had a lower employment rate than the general population (standardized ratio, .85; 95% CI, .77–.94). There were more PwSH at tertiary education level than expected (standardized ratio, 1.38; 95% CI, 1.17–1.61). HIV infection, poor physical health and mental health concerns were associated with a higher risk of unemployment in PwSH.Conclusion: Employment rate of PwSH is lower than that of the general population despite their higher education level. Target interventions focusing on determinants of difficult occupational integration could be helpful for PwSH.
- 20 July 2022
- Published by Wiley in Haemophilia
- Vol. 28 (6) , 962-976
Open AccessOccupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry
Introduction: Health of people with severe haemophilia (PwSH) improves thanks to the advancements in haemophilia care, giving them more opportunities in occupational integration. However, there is little literature on the occupational integration of PwSH.Objectives: The main objective of our study was to assess the occupational integration of PwSH and to compare it with that of the general population. The secondary objective was to study the association between individual characteristics (sociodemographic, clinical and psycho‐behavioural) and occupational integration of PwSH.Methods: A multicentre, non‐interventional, cross‐sectional study was conducted in 2018–2020 on PwSH, aged over 18 and under 65 years and included in the FranceCoag registry. Measurements included indicators of occupational integration, sociodemographic, clinical and psycho‐behavioural characteristics. The indicators of occupational integration were compared with those of the general population, using indirect standardization. The data of the general population were available from the National Institute of Statistics and Economic Studies (INSEE). Determinants of occupational integration were explored using structural equation modelling.Results: Of 1262 eligible people, 588 were included. PwSH had a lower employment rate than the general population (standardized ratio, .85; 95% CI, .77–.94). There were more PwSH at tertiary education level than expected (standardized ratio, 1.38; 95% CI, 1.17–1.61). HIV infection, poor physical health and mental health concerns were associated with a higher risk of unemployment in PwSH.Conclusion: Employment rate of PwSH is lower than that of the general population despite their higher education level. Target interventions focusing on determinants of difficult occupational integration could be helpful for PwSH.
- Open Access
- 9 September 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (9) , e28728
COVID-19 Health Crisis and Chronic Illness: Protocol for a Qualitative Study
Background: The acute nature of the COVID-19 pandemic has put a strain on health resources that are usually dedicated to chronic illnesses. Resulting changes in care practices and networks have had major repercussions on the experience of people with chronic disorders. Objective: This paper presents the protocol of the Parcours, Associations, Réseau, Chronicité, Organisation, Usagers, Retour d’expérience, Soins (PARCOURS)-COVID study. The aim of this study is to evaluate the effects of reorganization of the health system on the usual care network of patients with chronic illness, which fosters and qualifies the quality and continuum of care provided. The first objective of this study is to document these patients’ experiences through transformations and adaptations of their network, both in the practical dimension (ie, daily life and care) and subjective dimension (ie, psychosocial experience of illness and relationship to the health system). The second objective of the study is to understand and acknowledge these reorganizations during the COVID-19 lockdown and postlockdown periods. The third objective is to produce better adapted recommendations for patients with chronic illness and value their experience for the management of future health crisis. Methods: The PARCOURS-COVID study is a qualitative and participatory research involving patient organizations as research partners and members of these organizations as part of the research team. Three group of chronic diseases have been selected regarding the specificities of the care network they mobilize: (1) cystic fibrosis and kidney disease, (2) hemophilia, and (3) mental health disorders. Four consecutive phases will be conducted, including (1) preparatory interviews with medical or associative actors of each pathology field; (2) in-depth individual interviews with patients of each pathology, analyzed using the qualitative method of thematic analysis; (3) results of both these phases will then be triangulated through interviews with members of each patient’s care ecosystem; and finally, (4) focus groups will be organized to discuss the results with research participants (ie, representatives of chronic disease associations; patients; and actors of the medical, psychosocial, and family care network) in a research-action framework. Results: The protocol study has undergone a peer review by the French National Research Agency’s scientific committee and has been approved by the research ethical committee of the University of Paris (registration number: IRB 00012020-59, June 28, 2020). The project received funding from August 2020 through April 2021. Expected results will be disseminated in 2021 and 2022. Conclusions: Our findings will better inform the stakes of the current health crisis on the management of patients with chronic illness and, more broadly, any future crisis for a population deemed to be at risk. They will also improve health democracy by supporting better transferability of knowledge between the scientific and citizen communities. International Registered Report Identifier (IRRID): DERR1-10.2196/28728
- 9 September 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (9) , e28728
Open AccessCOVID-19 Health Crisis and Chronic Illness: Protocol for a Qualitative Study
Background: The acute nature of the COVID-19 pandemic has put a strain on health resources that are usually dedicated to chronic illnesses. Resulting changes in care practices and networks have had major repercussions on the experience of people with chronic disorders. Objective: This paper presents the protocol of the Parcours, Associations, Réseau, Chronicité, Organisation, Usagers, Retour d’expérience, Soins (PARCOURS)-COVID study. The aim of this study is to evaluate the effects of reorganization of the health system on the usual care network of patients with chronic illness, which fosters and qualifies the quality and continuum of care provided. The first objective of this study is to document these patients’ experiences through transformations and adaptations of their network, both in the practical dimension (ie, daily life and care) and subjective dimension (ie, psychosocial experience of illness and relationship to the health system). The second objective of the study is to understand and acknowledge these reorganizations during the COVID-19 lockdown and postlockdown periods. The third objective is to produce better adapted recommendations for patients with chronic illness and value their experience for the management of future health crisis. Methods: The PARCOURS-COVID study is a qualitative and participatory research involving patient organizations as research partners and members of these organizations as part of the research team. Three group of chronic diseases have been selected regarding the specificities of the care network they mobilize: (1) cystic fibrosis and kidney disease, (2) hemophilia, and (3) mental health disorders. Four consecutive phases will be conducted, including (1) preparatory interviews with medical or associative actors of each pathology field; (2) in-depth individual interviews with patients of each pathology, analyzed using the qualitative method of thematic analysis; (3) results of both these phases will then be triangulated through interviews with members of each patient’s care ecosystem; and finally, (4) focus groups will be organized to discuss the results with research participants (ie, representatives of chronic disease associations; patients; and actors of the medical, psychosocial, and family care network) in a research-action framework. Results: The protocol study has undergone a peer review by the French National Research Agency’s scientific committee and has been approved by the research ethical committee of the University of Paris (registration number: IRB 00012020-59, June 28, 2020). The project received funding from August 2020 through April 2021. Expected results will be disseminated in 2021 and 2022. Conclusions: Our findings will better inform the stakes of the current health crisis on the management of patients with chronic illness and, more broadly, any future crisis for a population deemed to be at risk. They will also improve health democracy by supporting better transferability of knowledge between the scientific and citizen communities. International Registered Report Identifier (IRRID): DERR1-10.2196/28728
- Open Access
- 12 March 2021
- Published by JMIR Publications Inc. in JMIR Preprints
COVID-19 Health Crisis and Chronic Illness: Protocol for a Qualitative Study (Preprint)
BACKGROUND The acute nature of the COVID-19 pandemic has put a strain on health resources that are usually dedicated to chronic illnesses. Resulting changes in care practices and networks have had major repercussions on the experience of people with chronic disorders. OBJECTIVE This paper presents the protocol of the Parcours, Associations, Réseau, Chronicité, Organisation, Usagers, Retour d’expérience, Soins (PARCOURS)-COVID study. The aim of this study is to evaluate the effects of reorganization of the health system on the usual care network of patients with chronic illness, which fosters and qualifies the quality and continuum of care provided. The first objective of this study is to document these patients’ experiences through transformations and adaptations of their network, both in the practical dimension (ie, daily life and care) and subjective dimension (ie, psychosocial experience of illness and relationship to the health system). The second objective of the study is to understand and acknowledge these reorganizations during the COVID-19 lockdown and postlockdown periods. The third objective is to produce better adapted recommendations for patients with chronic illness and value their experience for the management of future health crisis. METHODS The PARCOURS-COVID study is a qualitative and participatory research involving patient organizations as research partners and members of these organizations as part of the research team. Three group of chronic diseases have been selected regarding the specificities of the care network they mobilize: (1) cystic fibrosis and kidney disease, (2) hemophilia, and (3) mental health disorders. Four consecutive phases will be conducted, including (1) preparatory interviews with medical or associative actors of each pathology field; (2) in-depth individual interviews with patients of each pathology, analyzed using the qualitative method of thematic analysis; (3) results of both these phases will then be triangulated through interviews with members of each patient’s care ecosystem; and finally, (4) focus groups will be organized to discuss the results with research participants (ie, representatives of chronic disease associations; patients; and actors of the medical, psychosocial, and family care network) in a research-action framework. RESULTS The protocol study has undergone a peer review by the French National Research Agency’s scientific committee and has been approved by the research ethical committee of the University of Paris (registration number: IRB 00012020-59, June 28, 2020). The project received funding from August 2020 through April 2021. Expected results will be disseminated in 2021 and 2022. CONCLUSIONS Our findings will better inform the stakes of the current health crisis on the management of patients with chronic illness and, more broadly, any future crisis for a population deemed to be at risk. They will also improve health democracy by supporting better transferability of knowledge between the scientific and citizen communities. CLINICALTRIAL Institutional Review Board 00012020-59 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/28728
- 12 March 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCOVID-19 Health Crisis and Chronic Illness: Protocol for a Qualitative Study (Preprint)
BACKGROUND The acute nature of the COVID-19 pandemic has put a strain on health resources that are usually dedicated to chronic illnesses. Resulting changes in care practices and networks have had major repercussions on the experience of people with chronic disorders. OBJECTIVE This paper presents the protocol of the Parcours, Associations, Réseau, Chronicité, Organisation, Usagers, Retour d’expérience, Soins (PARCOURS)-COVID study. The aim of this study is to evaluate the effects of reorganization of the health system on the usual care network of patients with chronic illness, which fosters and qualifies the quality and continuum of care provided. The first objective of this study is to document these patients’ experiences through transformations and adaptations of their network, both in the practical dimension (ie, daily life and care) and subjective dimension (ie, psychosocial experience of illness and relationship to the health system). The second objective of the study is to understand and acknowledge these reorganizations during the COVID-19 lockdown and postlockdown periods. The third objective is to produce better adapted recommendations for patients with chronic illness and value their experience for the management of future health crisis. METHODS The PARCOURS-COVID study is a qualitative and participatory research involving patient organizations as research partners and members of these organizations as part of the research team. Three group of chronic diseases have been selected regarding the specificities of the care network they mobilize: (1) cystic fibrosis and kidney disease, (2) hemophilia, and (3) mental health disorders. Four consecutive phases will be conducted, including (1) preparatory interviews with medical or associative actors of each pathology field; (2) in-depth individual interviews with patients of each pathology, analyzed using the qualitative method of thematic analysis; (3) results of both these phases will then be triangulated through interviews with members of each patient’s care ecosystem; and finally, (4) focus groups will be organized to discuss the results with research participants (ie, representatives of chronic disease associations; patients; and actors of the medical, psychosocial, and family care network) in a research-action framework. RESULTS The protocol study has undergone a peer review by the French National Research Agency’s scientific committee and has been approved by the research ethical committee of the University of Paris (registration number: IRB 00012020-59, June 28, 2020). The project received funding from August 2020 through April 2021. Expected results will be disseminated in 2021 and 2022. CONCLUSIONS Our findings will better inform the stakes of the current health crisis on the management of patients with chronic illness and, more broadly, any future crisis for a population deemed to be at risk. They will also improve health democracy by supporting better transferability of knowledge between the scientific and citizen communities. CLINICALTRIAL Institutional Review Board 00012020-59 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/28728